Zhejiang, China

Yuting Cai

This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Technoderma Medicines Pte Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuting Cai. Retrieved from https://idiyas.com/inventor/yuting-cai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yuting Cai - Innovator in Small Molecule Compounds

Introduction

Yuting Cai is a notable inventor based in Zhejiang, China. She has made significant contributions to the field of medicinal chemistry, particularly in the development of small molecule compounds. Her work focuses on creating innovative solutions for medical applications.

Latest Patents

Yuting Cai holds a patent for a small molecule compound that serves as a highly efficient and specific JAK kinase inhibitor. This compound is characterized by its various forms, including stereoisomers, geometric isomers, tautomers, racemates, hydrates, solvates, metabolites, and pharmaceutically acceptable salts or prodrugs. The compound is particularly effective as a Tyk2 inhibitor and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor.

Career Highlights

Yuting Cai is currently associated with Technoderma Medicines Pte Ltd., where she continues to advance her research and development efforts. Her innovative approach has positioned her as a key player in the pharmaceutical industry.

Collaborations

Yuting collaborates with talented individuals such as Xiang Pan and Yang Wang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Yuting Cai's work in small molecule compounds exemplifies the impact of innovative research in the pharmaceutical field. Her contributions are paving the way for new therapeutic options and enhancing the understanding of JAK kinase inhibitors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…